x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Oncology for the Inquisitive Mind

Michael Fernando and Josh Hurwitz

Cancer is a fascinatingbut rapidly evolvingdiscipline- it"s a full-time job just keeping up to date. In this podcast,Dr Michael Fernando and Dr Joshua Hurwitz explorethe latest trials, research, and practice-changing updates,as well asregular interviews with renowned oncology specialists.Ideal for thosestarting their trainingjourney, established specialistsandanyone interested in medical science, oncological practice,or terrible jokes. Preferably all three. Hosted on Acast. See acast.com/privacy for

health & fitness medicine

All Episodes

19:51

118. ASCO 2024 - Sarcoma

Oncology for the Inquisitive Mind ·

2024/06/16

Today is the penultimate episode in our ASCO 2024 Odyssey. Michael and Josh have neglected sarcoma to date, but today is the day@ Sarcoma is rare, where clinician experience becomes paramount to treatment options and outcomes. They develop in soft tissues and bones and vary in origin, including deep soft tissue, bone, nerves, etc. Today, they explore three trials. The first is paclitaxel and avelumab in inoperable angiosarcoma, the second is perioperative radiotherapy with adjuvant immunotherapy in

en

25:27

117. ASCO 2024 - Central Nervous System

Oncology for the Inquisitive Mind ·

2024/06/15

Some consider the number 13 unlucky; fear of the number has its own name, "triskaidekaphobia." So it is perhaps somewhat fitting that day 13 of our ASCO Odyssey is dedicated to the cancer type with which scientists and doctors have had arguably the least luck in treating: central nervous system cancers. We still await CNS oncology's immunotherapy or EGFR/ALK moment, and unfortunately, as of ASCO 2024, that has not come yet. However, that has not stopped legions of incredibly dedicated and

en

28:06

116. ASCO 2024 - Early Lung Cancer & Mesothelioma

Oncology for the Inquisitive Mind ·

2024/06/14

ASCO 2024 beat many attendees' expectations with interesting and thought-provoking lung cancer and mesothelioma studies. While not all of these will change the face of patient treatment, they will add to a body of evidence for biomarkers and build on the blocks of tailoring treatment to patients.Links to studies discussed in this episode (subscription may be required):BEAT-meso: Link Checkmate 816 4 year update: LinkMIST5: LinkctDNA-Lung-DETECT: Link BEAT-SC: Link For more episodes, resources and

en

25:41

115. ASCO 2024 - Head and Neck Cancer

Oncology for the Inquisitive Mind ·

2024/06/13

Our coverage of ASCO 2024 has rounded the final bend, and the finish line is in sight. Today, Josh and Michael examine four studies in the head and neck cancer space. Today's studies include a novel, viral-driven vector that aims to increase the immune response to treatment, potential treatment for the very rare nasal squamous cell cancer, data supporting the treatment of patients with poor prognosis and head and neck patients, and a new, intensive immunotherapy treatment for nasopharyngeal cancer

en

23:50

114. ASCO 2024 - Early Colorectal Cancer

Oncology for the Inquisitive Mind ·

2024/06/12

ASCO 2024 never seems to end, and today, Michael and Josh do a bit of a backflip and report on the advancements in early colorectal cancer. Forever a confusing topic with PRODIGE23, OPRA, and many other rectal cancer trials and a spattering of neoadjuvant colorectal trials, the ability to redefine and provide clarity to this area is pertinent. Today, it heavily focuses on immunotherapy in the colon space with sintilimab and IBI310 battling it out with the old master pembrolizumab. The rectal

en

22:48

113. ASCO 2024 - Metastatic Colorectal Cancer

Oncology for the Inquisitive Mind ·

2024/06/11

Our 2024 ASCO epic trundles onto its next generation, advanced colorectal cancer. Over the last 10 years, treatment in this area has made incremental progress through the discovery of the clinically meaningful KRAS and BRAF mutation pathways and most recently with the potential for immunotherapy in the deficient mismatch repair (dMMR) and high microsatellite instability (MSI-H) subgroups. In this episode, Josh and Michael examine studies looking at KRAS G12C-mutated, HER2-positive and dMMR

en

29:05

112. ASCO 2024 - Upper Gastrointestinal and...

Oncology for the Inquisitive Mind ·

2024/06/10

Some oncologists may have already started counting down to ASCO 2025. However, Michael and Josh are still digesting the interesting world of ASCO 2024, specifically upper GI and Hepatobiliary Cancers and, like Aladdin, explicitly referring to the Disney 1992 cult classic featuring Robbin Williams, here to lie several diamonds in the rough.We cover perioperative FLOT in the metastatic setting, but most excitingly, it is a potentially new groundbreaking treatment for hepatocellular carcinoma.Links to

en

26:33

111. ASCO 2024 - Genitourinary Cancers (Prostate/Penile)

Oncology for the Inquisitive Mind ·

2024/06/09

The second of our two GU ASCO 2024 episodes focusses on prostate and penile cancer, two diseases at different ends of the therapeutic spectrum. Prostate cancer is one of the most common cancers in men, with well established, nuanced treatment paradigms and a glut of high-quality evidence. Penile SCC is a very rare cancer that tragically is much more common in low socioeconomic countries. Treatment options are as limited as available evidence, so any new studies of this cancer are very welcome. Are

en

26:44

110. ASCO 2024 - Genitourinary Cancers (Bladder/Kidney)

Oncology for the Inquisitive Mind ·

2024/06/08

Genitourinary Cancers dominated ASCO24 this year, and Josh and Michael's ASCO Odyssey needed two episodes to fit it all in. Join them as they board the Nautilus with Captain Nemo in search of the best trials to propel bladder and renal cancer to the forefront of your mind. This episode covers both the use of perioperative sacituzumab govitecan, avelumab as neoadjuvant therapy for bladder cancer and camrelizumab for previously treated advanced adrenocortical carcinoma. Not to be forgotten, they

en

37:43

109. ASCO 2024 - Early Breast Cancer

Oncology for the Inquisitive Mind ·

2024/06/07

Unbeknownst to Josh, we are already at Day 5 of our ASCO Odyssey, and like Odysseus arriving at Circe's island of Aeaea, we have arrived at the episode devoted to early Breast Cancer. Today we examine four very interesting studies, looking at alternative immunotherapy strategies with adjuvant avelumab, adjuvant endocrine therapy omission in low-ER positive disease, ctDNA in predicting disease recurrence, and a study that aims to change the very bedrock of breast cancer classification. Lots to

en

34:57

108. ASCO 2024 - Metastatic Brest Cancer

Oncology for the Inquisitive Mind ·

2024/06/06

Today, Michael and Josh approach a singular destiny to present their take on Metastatic Breast Cancer at ASCO 2024. Long has Breast Cancer been one of the most diagnosed cancers globally; these days, it leads the herd with effective treatment options and paradigm shifts that benefit millions of people on a massive scale. With CDK4/6 inhibitors, immunotherapy and antibody-drug conjugates, the arsenal of effective treatment tools continues to grow! Nothing excites an oncologist more than a good

en

33:47

107. ASCO 2024 - Gynaecological Cancer

Oncology for the Inquisitive Mind ·

2024/06/05

Day 3 of Oncology for the Inquisitive Mind's ASCO Odyssey and our hosts show no sign of flagging under this immense pressure, although Josh has started to give up on his famous segues. In this episode, our intrepid hosts tackle gynaecological cancers, reporting on four of their favourite studies from a packed field of gynaecological cancers. Will new treatment options for cervical cancer emerge? Will the sugical approach to recurrent ovarian cancer change? Is there still a place for single agent

en

31:26

106. ASCO 2024 - Melanoma

Oncology for the Inquisitive Mind ·

2024/06/04

As the sun rises on another day at ASCO, Michael and Josh are ready to hit the ground running to bring you the latest and greatest in all things oncology in Chicago has to offer. No greek mythology today, only a burning desire to bring you the biggest melanoma trials from ASCO24. Today, they pack a punch, tackling some intriguing phase 1 trials with tongue-twisting names where the novelty wears off pretty quickly!Links to articles discussed in this episode (subscription may be required):

en

37:46

105. ASCO 2024 - Metastatic Non Small Cell Lung Cancer

Oncology for the Inquisitive Mind ·

2024/06/03

"Tell me, Muse, the story of that resourceful man who was driven to wander far and wide after he had sacked Troy. He saw the cities of many people and he learnt their ways. Tell us this story, goddess daughter of Zeus, beginning at whatever point you will." So begins Homer's epic The Odyssey, the story of the titular hero Odysseus' long, long, LONG journey from the ruins of Troy to his home of Ithaca. Just as Odysseus set out from Troy, so do Michael and Josh begin an "odyssey" of their own. The

en

25:54

104. Metastatic Gastric and GOJ Cancer

Oncology for the Inquisitive Mind ·

2024/06/01

With ASCO upon us, Michael and Josh squeeze one more episode of their regular schedule to bring you an important update on gastric cancer. For context, the 5 year survival rate for metastatic gastric cancer is 6%, similar to that of pancreatic cancer. Despite improvement in survival due to the addition of nivolumab to chemotherapy (Checkmate 64), few therapies have significantly changed it's overall prognosis.This week Michael and Josh explore the addition of a LAG-3 inhibitor (relatlimab) to the

en

30:38

103. Metastatic Colorectal Cancer

Oncology for the Inquisitive Mind ·

2024/05/25

Oncology research never sits still, nor does the desire for better treatment options for metastatic colorectal cancer. Fifty percent of diagnosed cases develop metastatic spread during their disease course. This week, we look for the "SUNLIGHT" and investigate the combination of Lonsurf with Bevacizumab and using Fruquintinib with refractory metastatic colorectal cancer.Links to articles discussed in this episode (subscription may be required): FRESCO-2: Link SUNLIGHT: LinkFor more episodes,

en

33:24

102. Hepatocellular Carcinoma

Oncology for the Inquisitive Mind ·

2024/05/18

Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer in the world and the third or fourth leading cause of death (depending on where you do your research). Over 70% of cases are in Asian countries, predominantly due to high rates of endemic hepatitis infections.This week, we climb a mountain in search of treatment options and advancements in this orphan cancer. Two trials are discussed: The first is HIMALAYA comparing durvalumab and tremelimumab versus the old incumbent sorafenib

en

15:43

Oncosnacks 14: Bevacizumab Toxicity (Part 1)

Oncology for the Inquisitive Mind ·

2024/05/14

In many parts of the world, Bevacizumab is an important component of the treatment of glioblastoma, colorectal, hepatocellular and ovarian cancers. However, with such widespread use inevitably comes toxicity. Side effects related to bevacizumab are not your garden-variety chemotherapy side effects, nor are they similar to toxicity from immunotherapy. Rather, they stand apart, unique amongst our systemic therapies.In their latest Onconack, Josh and Michael take a look at two of the most commonly

en

33:38

101. Castration-Resistant Prostate Cancer Update

Oncology for the Inquisitive Mind ·

2024/05/11

As many philosophers have noted, life often travels in cycles. Almost two years and more than 100 episodes ago, on a virtual call far far away, two young oncologists started on a journey to bring the latest oncology evidence to anyone with ears and the will to listen. Now, for episode number 101, Josh and Michael return to where it all started: prostate cancer. Much has changed in the (nearly) two years since that episode, and so in this episode, our hosts provide an update on two more recent

en

28:19

100. 100th Episode Bonanza

Oncology for the Inquisitive Mind ·

2024/05/04

For 100 episodes, Josh and Michael have brought to your ears the latest and greatest in oncology research and treatment. In this episode, we will take a trip down memory lane, speaking about our journey up to this point, our favourite guests and favourite trials, and give you a glimpse of what the future holds for Oncology for the Inquisitive Mind. If we're honest, we never expected to get this far, and we have you, our wonderful audience to thank for that. We are so grateful for your support, you

en

195 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

Podcasts Archives - Extreme Health Radio

Justin Stellman

Oncology for the Inquisitive Mind

Michael Fernando and Josh Hurwitz

Good Sleep: Positive Affirmations

Optimal Living Daily | Sleepy Meditation

Johannes Hansen Podcast

Johannes Hansen